Genmab | GEN - Operating Expenses


Genmab reported DKK798M in Operating Expenses for its fiscal quarter ending in December of 2025.





Operating Expenses Change Date
Agios Pharmaceuticals USD 141.54M 11.8M Dec/2025
Almirall EUR 517.4M 32K Dec/2025
Amarin USD 51.48M 113K Dec/2025
Amgen USD 5.9B 773M Dec/2025
argenx SE USD 914.57M 137.58M Dec/2025
AstraZeneca USD 12.53B 4.16B Dec/2025
Bayer EUR 10.33B 126M Dec/2025
BioMarin Pharmaceutical USD 676.18M 131.65M Dec/2025
Demant DKK 9.63B 241M Dec/2025
Exelixis USD 362.75M 21.35M Dec/2025
Fresenius Medical Care EUR 4.41B 27.91M Dec/2025
Galapagos EUR 120.26M 7.43M Dec/2025
Genmab DKK 798M 235M Dec/2025
GlaxoSmithKline GBP 7.18B 1.42B Dec/2025
GN Store Nord DKK 4.11B 490M Dec/2025
GRIFOLS EUR 1.71B 193M Dec/2025
Hikma Pharmaceutical USD 1.34B 702M Dec/2025
Insmed USD 513.55M 109.86M Dec/2025
Lonza CHF 2.9B 184M Jun/2025
Merck EUR 4.78B 669M Dec/2025
Novartis USD 9.8B 61M Dec/2025
Regeneron Pharmaceuticals USD 2.99B 27.97B Dec/2025
Roche Holding CHF 21.01B 10.84B Dec/2025
Sanofi EUR 10.51B 1.21B Dec/2025
UCB EUR 2.96B 196M Dec/2025